Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol in hyperuricemic chronic kidney disease
ACTRN12614000320651Phase 4Completed
- Sponsor
- Dilara Bayram
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of allopurinol in chronic kidney disease (CKD) (2 arms), sponsored by Dilara Bayram. Primary endpoint: Creatinine clearance. Started Jan 2012; status: completed.
02
Drugs
allopurinol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12614000320651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000320651.